

# 抗癌藥物治療指引

## 肺癌

### 討論日期

團隊修訂：2019/12/24

核備日期：2020/3/31

## 《肺癌抗癌藥物治療指引》

### Small Cell Lung Cancer

#### Chemotherapy as Primary or Adjuvant Therapy

##### Limited Stage (maximum of 4-6 cycles):

During chemotherapy + RT, Cisplatin/Etoposide is recommended

The use of myeloid growth factors is not recommended during CCRT

藥品名	劑量* mg/m <sup>2</sup>	給藥日	頻率	週期	參考文獻
Cisplatin	75	1	Q3W	4-6	8
Etoposide	100	1-3	Q3W	4-6	

藥品名*	劑量 mg/m <sup>2</sup>	給藥日	頻率	週期	參考文獻
Cisplatin	25	1-3	Q3W	4-6	8
Etoposide	100	1-3	Q3W	4-6	

藥品名	劑量 mg/m <sup>2</sup>	給藥日	頻率	週期	參考文獻
Carboplatin	AUC 5-6	1	Q3W	4-6	1
Etoposide	100	1-3	Q3W	4-6	

##### Extensive Stage (maximum of 4-6 cycles):

藥品名	劑量 mg/m <sup>2</sup>	給藥日	頻率	週期	參考文獻
Atezolizumab	1200 mg	1	Q3W		9
Carboplatin	AUC 5	1	Q3W	4	
Etoposide	100	1-3	Q3W	4	

藥品名	劑量 mg/m <sup>2</sup>	給藥日	頻率	週期	參考文獻
Cisplatin	75-80	1	Q3W	4-6	2, 3
Etoposide	100	1-3	Q3W	4-6	

藥品名	劑量 mg/m <sup>2</sup>	給藥日	頻率	週期	參考文獻
Carboplatin	AUC 5-6	1	Q3W	4-6	4
Etoposide	100	1-3	Q3W	4-6	

##### Subsequent Chemotherapy:

Clinical trial preferred

Relapse <6 months, PS 0-2:

藥品名	劑量 mg/m <sup>2</sup>	給藥日	頻率	週期	參考文獻
Topotecan	1.5	1-5	Q3W		5

藥品名	劑量 mg/m <sup>2</sup>	給藥日	頻率	週期	參考文獻
Topotecan	2.3 PO	1-5	Q3W		6

藥品名	劑量 mg/m <sup>2</sup>	給藥日	頻率	週期	參考文獻
Cyclophosphamide	1000	1	Q3W		5
Doxorubicin	45	1	Q3W		
Vincristine	2 mg	1	Q3W		

藥品名	劑量 mg/m <sup>2</sup>	給藥日	頻率	週期	參考文獻
Nivolumab	3 mg/kg	1	Q2W		7

藥品名	劑量 mg/m <sup>2</sup>	給藥日	頻率	週期	參考文獻
Nivolumab	3 mg/kg	1	Q2W		7
Ipilimumab	1 mg/kg	1	Q2W		

藥品名	劑量 mg/m <sup>2</sup>	給藥日	頻率	週期	參考文獻
Pembrolizumab	200 mg	1	Q3W		10

\*三院有個別版本

## 參考文獻

1. Skarlos DV, Samantas E, Briassoulis E, et al. Randomized comparison of early versus late hyperfractionated thoracic irradiation concurrently with chemotherapy in limited disease small-cell lung cancer: a randomized phase II study of the Hellenic Cooperative Oncology Group (HeCOG). *Ann Oncol* 2001;12(9):1231-1238.
2. Spigel R, Townley PM, Waterhouse DM, et al. Randomized phase II study of bevacizumab in combination with chemotherapy in previously untreated extensive-stage small-cell lung cancer: results from the SALUTE trial. *J Clin Oncol* 2011;29:2215-2222.
3. Niell HB, Herndon JE, Miller AA, et al. Randomized phase III Intergroup trial of etoposide and cisplatin with or without paclitaxel and granulocyte-colony stimulating factor in patients with extensive-stage small-cell lung cancer: Cancer and Leukemia Group B trial 9732. *J Clin Oncol* 2005;23:3752-3759.
4. Okamoto H, Watanabe K, Nishiwaki Y, et al. Phase II study of area under the plasmaconcentration-versus-time curve-based carboplatin plus standard-dose intravenous etoposide in elderly patients with small cell lung cancer. *J Clin Oncol* 1999;17(11):3540-3545.

5. von Pawel J, Schiller JH, Shepherd FA, et al. Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer. *J Clin Oncol* 1999;17(2):658-667.
6. O'Brien ME, Ciuleanu TE, Tsekov H, et al. Phase III trial comparing supportive care alone with supportive care with oral topotecan in patients with relapsed small-cell lung cancer. *J Clin Oncol*. 2006;24:5441-5447.
7. Atonia SJ, Lopez-Martin JA, Bendell J, et al. Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial. *Lancet Oncol* 2016;17:883-895.
8. Faivre-Finn C, Snee M, et al. Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT): an open-label, phase 3, randomised, superiority trial. *Lancet Oncol* 2017;18:1116-1125.
9. Leora Horn, Aaron S. Mansfield, et al. First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer. *N Engl Med* 2018;[Epub ahead of print].
10. Hyun Cheol Chung, Jose A. Lopez-Martin, et al. Phase 2 study of pembrolizumab in advanced small-cell lung cancer (SCLC): KEYNOTE-158. *J Clin Oncol* 2018;36:Abstract 8506.

## Non-Small Cell Lung Cancer

### Adjuvant Therapy

藥品名	劑量 mg/m <sup>2</sup>	給藥日	頻率	週期	參考文獻
Cisplatin	80	1	Q3W	4	1-3, 24
Vinorelbine	30	1, 8	Q3W	4	

藥品名	劑量 mg/m <sup>2</sup>	給藥日	頻率	週期	參考文獻
Cisplatin	75	1	Q3W	4	19
Vinorelbine	60 PO	1, 8	Q3W	4	

藥品名	劑量 mg/m <sup>2</sup>	給藥日	頻率	週期	參考文獻
Cisplatin	80	1	Q3W	4	4
Gemcitabine	1250	1, 8	Q3W	4	

藥品名	劑量 mg/m <sup>2</sup>	給藥日	頻率	週期	參考文獻
Cisplatin	75	1	Q3W	4	5
Docetaxel	75	1	Q3W	4	

藥品名	劑量 mg/m <sup>2</sup>	給藥日	頻率	週期	參考文獻
Cisplatin	75	1	Q3W	4	6
Pemetrexed	500	1	Q3W	4	

藥品名	劑量 mg/m <sup>2</sup>	給藥日	頻率	週期	參考文獻
UFUR	200 PO BID/TID				20

藥品名	劑量 mg/m <sup>2</sup>	給藥日	頻率	週期	參考文獻
Carboplatin	AUC 5	1	Q3W	4	12
Pemetrexed	500	1	Q3W	4	

藥品名	劑量 mg/m <sup>2</sup>	給藥日	頻率	週期	參考文獻
Carboplatin	AUC 5	1	Q3W	4	13
Gemcitabine	1000	1, 8	Q3W	4	

藥品名	劑量 mg/m <sup>2</sup>	給藥日	頻率	週期	參考文獻
Carboplatin	AUC 6	1	Q3W	4	14
Paclitaxel	200	1	Q3W	4	

藥品名*	劑量 mg/m <sup>2</sup>	給藥日	頻率	週期	參考文獻
Cisplatin	100	1	Q4W	4	21
Etoposide	100	1-3	Q4W	4	

## Neoadjuvant Therapy

藥品名	劑量 mg/m <sup>2</sup>	給藥日	頻率	週期	參考文獻
Cisplatin	80	1	Q3W	4	1-3, 24
Vinorelbine	30	1, 8	Q3W	4	

藥品名	劑量 mg/m <sup>2</sup>	給藥日	頻率	週期	參考文獻
Cisplatin	75	1	Q3W	4	19
Vinorelbine	60 PO	1, 8	Q3W	4	

藥品名	劑量 mg/m <sup>2</sup>	給藥日	頻率	週期	參考文獻
Cisplatin	80	1	Q3W	4	4
Gemcitabine	1250	1, 8	Q3W	4	

藥品名	劑量 mg/m <sup>2</sup>	給藥日	頻率	週期	參考文獻
Cisplatin	75	1	Q3W	4	5
Docetaxel	75	1	Q3W	4	

藥品名	劑量 mg/m <sup>2</sup>	給藥日	頻率	週期	參考文獻
Cisplatin	75	1	Q3W	4	6
Pemetrexed	500	1	Q3W	4	

藥品名	劑量 mg/m <sup>2</sup>	給藥日	頻率	週期	參考文獻
UFUR	200 PO BID/TID				20

藥品名	劑量 mg/m <sup>2</sup>	給藥日	頻率	週期	參考文獻
Carboplatin	AUC 5	1	Q3W	4	12
Pemetrexed	500	1	Q3W	4	

藥品名	劑量 mg/m <sup>2</sup>	給藥日	頻率	週期	參考文獻
Carboplatin	AUC 5	1	Q3W	4	13
Gemcitabine	1000	1, 8	Q3W	4	

藥品名	劑量 mg/m <sup>2</sup>	給藥日	頻率	週期	參考文獻
Carboplatin	AUC 6	1	Q3W	4	14
Paclitaxel	200	1	Q3W	4	

藥品名*	劑量 mg/m <sup>2</sup>	給藥日	頻率	週期	參考文獻
Cisplatin	100	1	Q4W	4	21
Etoposide	100	1-3	Q4W	4	

## Chemotherapy Regimens Used with Radiation Therapy

### Concurrent chemotherapy/RT regimens

Regimens can be used as neoadjuvant/preoperative/induction chemoradiotherapy

Regimens can be used as adjuvant or definitive concurrent chemotherapy/RT

藥品名	劑量 mg/m <sup>2</sup>	給藥日	頻率	週期	參考文獻
Cisplatin	50	1, 8	Q4W	2	23
Etoposide	50	1-5	Q4W	2	

藥品名	劑量 mg/m <sup>2</sup>	給藥日	頻率	週期	參考文獻
Cisplatin	50	1, 8	Q4W	2	7, 8
Etoposide	50mg PO BID	1, 2, 5, 6	QW	10	

藥品名	劑量 mg/m <sup>2</sup>	給藥日	頻率	週期	參考文獻
Carboplatin	AUC 5	1	Q3W	4	9
Pemetrexed	500	1	Q3W	4	

藥品名	劑量 mg/m <sup>2</sup>	給藥日	頻率	週期	參考文獻
Cisplatin	75	1	Q3W	3	10
Pemetrexed	500	1	Q3W	3 + 4 (additional)	

藥品名	劑量 mg/m <sup>2</sup>	給藥日	頻率	週期	參考文獻
Paclitaxel	45-50	1	QW		11
Carboplatin	AUC 2	1	QW		
± Paclitaxel	200	1	Q3W	2 (additional)	
± Carboplatin	AUC 6	1	Q3W	2 (additional)	

### Consolidation therapy

Unresectable stage III, PS 0-1, no progression after ≥ 2 cycles of CCRT

藥品名	劑量 mg/m <sup>2</sup>	給藥日	頻率	週期	參考文獻
Durvalumab	10 mg/kg	1	Q2W	24	25

### Sequential Chemotherapy/RT Regimens (Adjuvant):

As all the neoadjuvant/adjuvant chemotherapy regimens

### Target Therapy

EGFR mutation positive

藥品名	劑量 mg/m <sup>2</sup>	給藥日	頻率	週期	參考文獻
Erlotinib	150 mg PO QD AC				15

藥品名	劑量 mg/m <sup>2</sup>	給藥日	頻率	週期	參考文獻
Afatinib	40 mg PO QD AC				16

藥品名	劑量 mg/m <sup>2</sup>	給藥日	頻率	週期	參考文獻
Gefitinib	250 mg PO QD				17

藥品名*	劑量 mg/m <sup>2</sup>	給藥日	頻率	週期	參考文獻
Osimertinib	80 mg PO QD				22

### ALK positive

藥品名	劑量 mg/m <sup>2</sup>	給藥日	頻率	週期	參考文獻
Crizotinib	250 mg PO BID				18

藥品名*	劑量 mg/m <sup>2</sup>	給藥日	頻率	週期	參考文獻
Alectinib	600 mg		BID		27, 28

藥品名*	劑量 mg/m <sup>2</sup>	給藥日	頻率	週期	參考文獻
Ceritinib	450 mg		QD		29

藥品名*	劑量 mg/m <sup>2</sup>	給藥日	頻率	週期	參考文獻
Brigatinib	90 mg (180 mg)	d1-7 (d8 after)	QD		30

藥品名*	劑量 mg/m <sup>2</sup>	給藥日	頻率	週期	參考文獻
Lorlatinib	100 mg		QD		31

### ROS1 positive

藥品名*	劑量 mg/m <sup>2</sup>	給藥日	頻率	週期	參考文獻
Crizotinib	250 mg		BID		32

藥品名*	劑量 mg/m <sup>2</sup>	給藥日	頻率	週期	參考文獻
Ceritinib	450 mg		QD		33

\*三院有個別版本

### 參考文獻

1. Winton T, Livingston R, Johnson D, et al. Vinorelbine plus cisplatin vs. observation in resected non-small-lung cancer. N Engl J Med 2005;352:2589-2597.
2. Arriagada R, Bergman B, Dunant A, et al. The International Adjuvant Lung Cancer Trial Collaborative Group. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small cell lung cancer. N Engl J Med 2004;350:351-360.



3. Douillard JY, Rosell R, De Lena M, et al. Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial. *Lancet Oncol* 2006;7:719-727.
4. Pérol M, Chouaid C, Pérol D, et al. Randomized, phase III study of gemcitabine or erlotinib maintenance therapy versus observation, with predefined second-line treatment, after cisplatin-gemcitabine induction chemotherapy in advanced non-small-cell lung cancer. *J Clin Oncol* 2012;30:3516-3524.
5. Fossella F, Pereira JR, von Pawel J, et al. Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group. *J Clin Oncol* 2003;21:3016-3024.
6. Kreuter M, Vansteenkiste J, Fishcer JR, et al. Randomized phase 2 trial on refinement of early-stage NSCLC adjuvant chemotherapy with cisplatin and pemetrexed versus cisplatin and vinorelbine: the TREAT study. *Ann Oncol* 2013;24:986-992.
7. Albain KS, Crowley JJ, Turrisi AT III, et al. Concurrent cisplatin, etoposide, and chest radiotherapy in pathologic stage IIIB non-small-cell lung cancer: A Southwest Oncology Group Phase II Study, SWOG 9019. *J Clin Oncol* 2002;20:3454-3460.
8. Curran WJ Jr, Paulus R, Langer CJ, et al. Sequential vs. concurrent chemoradiation for stage III non-small cell lung cancer: randomized phase III trial RTOG 9410. *J Natl Cancer Inst.* 2011;103:1452-1460.
9. Govindan R, Bogart J, Stinchcombe T, et al. Randomized phase II study of pemetrexed, carboplatin, and thoracic radiation with or without cetuximab in patients with locally advanced unresectable non-small-cell lung cancer: Cancer and Leukemia Group B trial 30407. *J Clin Oncol* 2011;29:3120-3125.
10. Choy H, Gerber DE, Bradley JD, et al. Concurrent pemetrexed and radiation therapy in the treatment of patients with inoperable stage III non-small cell lung cancer: a systematic review of completed and ongoing studies. *Lung Cancer* 2015;87:232-240.
11. Bradley JD, Paulus R, Komaki R, et al. Standard-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomized, two-by-two factorial phase 3 study. *Lancet Oncol* 2015;16:187-199.
12. Zhang L, Ou W, Liu Q, et al. Pemetrexed plus carboplatin as adjuvant chemotherapy in patients with curative resected non-squamous non-small cell lung cancer. *Thoracic Cancer.* 2014;5(1):50-56.
13. Usami N, Yokoi K, Hasegawa Y, et al. Phase II study of carboplatin and gemcitabine as adjuvant chemotherapy in patients with completely resected non-small cell lung cancer: a report from the Central Japan Lung Study Group, CJLSG 0503 trial. *Int J Clin Oncol.* 2010;15(6):583-7.
14. Strauss GM, Herndon JE, Maddaus MA, et al. Adjuvant paclitaxel plus carboplatin compared

- with observation in stage IB non-small-cell lung cancer: CALGB 9633 with the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups. *J Clin Oncol*. 2008;26(31):5043-51.
15. Product Information: TARCEVA(R) oral tablets, erlotinib oral tablets. OSI Pharmaceuticals, LLC (per FDA), Farmingdale, NY, 2013.
  16. Product Information: GILOTRIF(TM) oral tablets, afatinib oral tablets. Boehringer Ingelheim Pharmaceuticals, Inc. (per FDA), Ridgefield, CT, 2013.
  17. Product Information: IRESSA(R) oral tablets, gefitinib oral tablets. AstraZeneca Pharmaceuticals (per FDA), Wilmington, DE, 2015.
  18. Product Information: XALKORI(R) oral capsules, crizotinib oral capsules. Pfizer Labs (per FDA), New York, NY, 2013.
  19. Krzakowski M, Provencio M, Utracka-Hutka B, et al. Oral vinorelbine and cisplatin as induction chemotherapy and concomitant chemo-radiotherapy in stage III non-small cell lung cancer: final results of an international phase II trial. *J Thorac Oncol*. 2008 Sep;3(9):994-1002.
  20. Product Information: UFUR Capsule. tegafur, uracil oral capsules. 2015.
  21. Arriagada R, Bergman B, Dunant A, et al. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. *N Engl J Med*. 2004;350(4):351-360.
  22. Mok TS, Wu YL, Ahn MJ, et al. Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer. *N Engl J Med*. 2017;376(7):629-640.
  23. J. Liang, N. Bi, S. Wu, et al. Etoposide and cisplatin versus paclitaxel and carboplatin with concurrent thoracic radiotherapy in unresectable stage III non-small cell lung cancer: a multicenter randomized phase III trial. *Ann Oncol*. 2017;28(4):777-783.
  24. Szilasi M, Müller V, Juhász E, et al. Cisplatin-vinorelbine chemotherapy in non-small cell lung cancer is safe and well tolerated: results of a retrospective Hungarian clinical data analysis. *Expert Opin Drug Saf*. 2009 Jan;8(1):9-14.
  25. Antonia SJ, Villegas A, Daniel D, et al. Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC. *N Engl J Med*. 2018;379(24):2342-2350.
  26. Wu YL, Cheng Y, Zhou X, et al. Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial. *Lancet Oncol*. 2017;18(11):1454-1466.
  27. Peters S, Camidge DR, Shaw AT, et al. Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung Cancer. *N Engl J Med*. 2017;377(9):829-838.
  28. Hida T, Nokihara H, Kondo M, et al. Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial. *Lancet Oncol*. 2017;390(10089):29-39.
  29. Soria JC, Tan DSW, Chiari R, et al. First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study. *Lancet Oncol*. 2017;389(10072):917-929.

30. Camidge DR, Kim HR, Ahn MJ, et al. Brigatinib versus Crizotinib in ALK-Positive Non-Small-Cell Lung Cancer. *N Engl J Med*. 2018;379(21):2027-2039.
31. Solomon BJ, Besse B, Bauer TM, et al. Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study. *Lancet Oncol*. 2018;19(12):1654-1667.
32. Shaw AT, Ou SH, Bang YJ, et al. Crizotinib in ROS1-rearranged non-small-cell lung cancer. *N Engl J Med*. 2014;371(21):1963-71.
33. Lim SM, Kim HR, Lee JS, et al. Open-Label, Multicenter, Phase II Study of Ceritinib in Patients With Non-Small-Cell Lung Cancer Harboring ROS1 Rearrangement. *J Clin Oncol*. 2017;35(23):2613-2618.

## Systemic Therapy for Advanced or Metastatic Disease of NSCLC

### 1<sup>st</sup> Line Systemic Therapy Options

#### Adenocarcinoma, large cell, NSCLC NOS (PS 0-1)

#### No contraindications to the addition of Pembrolizumab or Atezolizumab

藥品名	劑量 mg/m <sup>2</sup>	給藥日	頻率	週期	參考文獻
Pembrolizumab	200 mg	1	Q3W	4	28
Carboplatin	AUC 6	1	Q3W	4	
Pemetrexed	500	1	Q3W	4	

藥品名	劑量 mg/m <sup>2</sup>	給藥日	頻率	週期	參考文獻
Pembrolizumab	200 mg	1	Q3W	35	29
Cisplatin	75	1	Q3W		
Pemetrexed	500	1	Q3W		

藥品名	劑量 mg/m <sup>2</sup>	給藥日	頻率	週期	參考文獻
Atezolizumab	1200 mg	1	Q3W	6-PD	30
Bevacizumab	15 mg/kg	1	Q3W	6-PD	
Cisplatin	75	1	Q3W	6	
Pemetrexed	500	1	Q3W	6	

#### Contraindications to the Addition of Pembrolizumab or Atezolizumab

藥品名	劑量 mg/m <sup>2</sup>	給藥日	頻率	週期	參考文獻
Bevacizumab	15 mg/kg	1	Q3W	6-PD	1
Carboplatin	AUC 6	1	Q3W	6	
Paclitaxel	200	1	Q3W	6	

藥品名	劑量 mg/m <sup>2</sup>	給藥日	頻率	週期	參考文獻
Bevacizumab	15 mg/kg	1	Q3W	4-PD	2
Carboplatin	AUC 6	1	Q3W	4	
Pemetrexed	500	1	Q3W	4-PD	

藥品名	劑量 mg/m <sup>2</sup>	給藥日	頻率	週期	參考文獻
Bevacizumab	7.5 mg/kg	1	Q3W	4	3
Cisplatin	75	1	Q3W	4	
Pemetrexed	500	1	Q3W	4	

藥品名	劑量 mg/m <sup>2</sup>	給藥日	頻率	週期	參考文獻
Nab-Paclitaxel	100	1, 8, 15	Q3W	6-PD	4
Carboplatin	AUC 6	1	Q3W	6-PD	

藥品名	劑量 mg/m <sup>2</sup>	給藥日	頻率	週期	參考文獻
Carboplatin	AUC 6		Q3W		5
Docetaxel	75		Q3W		

藥品名	劑量 mg/m <sup>2</sup>	給藥日	頻率	週期	參考文獻
Carboplatin	AUC 4-5	1	Q4W		7
Etoposide	50mg PO BID	1-14 or 1-21	Q4W		

藥品名	劑量 mg/m <sup>2</sup>	給藥日	頻率	週期	參考文獻
Carboplatin	AUC 5	1	Q4W	4	8
Gemcitabine	1000	1, 8, 15	Q4W	4	

藥品名	劑量 mg/m <sup>2</sup>	給藥日	頻率	週期	參考文獻
Carboplatin	AUC 6	1	Q3W		9
Paclitaxel	200	1	Q3W		

藥品名	劑量 mg/m <sup>2</sup>	給藥日	頻率	週期	參考文獻
Carboplatin	AUC 6	1	Q3W	6	10
Pemetrexed	500	1	Q3W	6	

藥品名	劑量 mg/m <sup>2</sup>	給藥日	頻率	週期	參考文獻
Cisplatin	75	1	Q3W		5
Docetaxel	75	1	Q3W		

藥品名	劑量 mg/m <sup>2</sup>	給藥日	頻率	週期	參考文獻
Cisplatin	100	1	Q3W		11
Etoposide	100	1-3	Q3W		

藥品名	劑量 mg/m <sup>2</sup>	給藥日	頻率	週期	參考文獻
Cisplatin	80	1	Q3W		9
Gemcitabine	1000	1, 8	Q3W		

藥品名	劑量 mg/m <sup>2</sup>	給藥日	頻率	週期	參考文獻
Cisplatin	75	1	Q3W	6	12
Gemcitabine	1250	1, 8	Q3W	6	

藥品名	劑量 mg/m <sup>2</sup>	給藥日	頻率	週期	參考文獻
Paclitaxel	135	1	Q3W		13
Cisplatin	75	2	Q3W		

藥品名	劑量 mg/m <sup>2</sup>	給藥日	頻率	週期	參考文獻
Cisplatin	75	1	Q3W		12
Pemetrexed	500	1	Q3W		

藥品名	劑量 mg/m <sup>2</sup>	給藥日	頻率	週期	參考文獻
Gemcitabine	1000	1, 8	Q3W	8	14
Docetaxel	85	8	Q3W	8	

藥品名	劑量 mg/m <sup>2</sup>	給藥日	頻率	週期	參考文獻
Gemcitabine	1000	1, 8	Q3W	6	15
Vinorelbine	25	1, 8	Q3W	6	

## Adenocarcinoma, large cell, NSCLC NOS (PS 2)

藥品名	劑量 mg/m <sup>2</sup>	給藥日	頻率	週期	參考文獻
Nab-Paclitaxel	260	1	Q3W		16

藥品名	劑量 mg/m <sup>2</sup>	給藥日	頻率	週期	參考文獻
Nab-Paclitaxel	100	1, 8, 15	Q4W		17

藥品名	劑量 mg/m <sup>2</sup>	給藥日	頻率	週期	參考文獻
Carboplatin	AUC 6	1	Q3W	6	18
Nab-Paclitaxel	100	1, 8, 15	Q3W	6	

藥品名	劑量 mg/m <sup>2</sup>	給藥日	頻率	週期	參考文獻
Carboplatin	AUC 6	1	Q3W		5
Docetaxel	75	1	Q3W		

藥品名	劑量 mg/m <sup>2</sup>	給藥日	頻率	週期	參考文獻
Carboplatin	325	1			6
Etoposide	100	1-3			

藥品名	劑量 mg/m <sup>2</sup>	給藥日	頻率	週期	參考文獻
Carboplatin	AUC 4-5	1	Q4W		7
Etoposide	50mg PO BID	1-14 or 1-21	Q4W		

藥品名	劑量 mg/m <sup>2</sup>	給藥日	頻率	週期	參考文獻
Carboplatin	AUC 5	1	Q4W	4	8
Gemcitabine	1000	1, 8, 15	Q4W		

藥品名	劑量 mg/m <sup>2</sup>	給藥日	頻率	週期	參考文獻
Carboplatin	AUC 6	1	Q3W		9
Paclitaxel	200	1	Q3W		

藥品名	劑量 mg/m <sup>2</sup>	給藥日	頻率	週期	參考文獻
Carboplatin	AUC 6	1	Q3W	6	10
Pemetrexed	500	1	Q3W		

藥品名	劑量 mg/m <sup>2</sup>	給藥日	頻率	週期	參考文獻
Docetaxel	75	1	Q3W	6	19, 20

藥品名	劑量 mg/m <sup>2</sup>	給藥日	頻率	週期	參考文獻
Gemcitabine	1250	1, 8, 15	Q4W	9	21

藥品名	劑量 mg/m <sup>2</sup>	給藥日	頻率	週期	參考文獻
Gemcitabine	1250	1, 8	Q3W	6	22, 23

藥品名	劑量 mg/m <sup>2</sup>	給藥日	頻率	週期	參考文獻
Gemcitabine	1000	1, 8	Q3W	8	14
Docetaxel	85	8	Q3W	8	

藥品名	劑量 mg/m <sup>2</sup>	給藥日	頻率	週期	參考文獻
Gemcitabine	1000	1, 8	Q3W	6	15
Vinorelbine	25	1, 8	Q3W	6	

藥品名	劑量 mg/m <sup>2</sup>	給藥日	頻率	週期	參考文獻
Paclitaxel	225	1	Q3W	6	24

藥品名	劑量 mg/m <sup>2</sup>	給藥日	頻率	週期	參考文獻
Paclitaxel	80	1, 8, 15	Q4W	4	25, 26

藥品名	劑量 mg/m <sup>2</sup>	給藥日	頻率	週期	參考文獻
Pemetrexed	500	1	Q3W		27

\*三院有個別版本

### 參考文獻

1. Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small lung cancer. *N Engl J Med* 2006;355:2542-2550.
2. Patel JD, Socinski MA, Garon EB, et al. Pointbreak: a randomized phase III study of pemetrexed plus carboplatin and bevacizumab followed by maintenance pemetrexed and bevacizumab versus paclitaxel plus carboplatin and bevacizumab followed by maintenance bevacizumab in patients with stage IIIB or IV nonsquamous non-small cell lung cancer. *J Clin Oncol* 2013;31:3004-3011.
3. Barlesi F, Scherpereel A, Rittmeyer A, et al. Randomized phase III trial of maintenance bevacizumab with or without pemetrexed after first-line induction with bevacizumab, cisplatin, and pemetrexed in advanced nonsquamous non-small cell lung cancer: AVAPERL. *J Clin Oncol* 2013;31:3004-3011.
4. Socinski MA, Bondarenko I, Karaseva NA, et al. Weekly nab-paclitaxel in combination with carboplatin versus solvent-based paclitaxel plus carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer: final results of a phase III trial. *J Clin Oncol* 2012;30:2055-2062.
5. Fossella F, Periera JR, von Pawel J, et al. Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group. *J Clin Oncol* 2003;21(16):3016-3024.
6. Klastersky J, Sculier JP, Lacroix H, et al. A randomized study comparing cisplatin or carboplatin with etoposide in patients with advanced non-small-cell lung cancer: European Organization for Research and Treatment of Cancer Protocol 07861. *J Clin Oncol* 1990;8:1556-1562.

7. Frasci G, Comella P, Panza N, et al. Carboplatin-oral etoposide personalized dosing in elderly non-small cell lung cancer patients. Gruppo Oncologico Cooperativo Sud-Italia. *Eur J Cancer*. 1998;34:1710-1714.
8. Danson S, Middleton MR, O'Byrne KJ, et al. Phase III trial of gemcitabine and carboplatin versus mitomycin, ifosfamide, and cisplatin or mitomycin, vinblastine, and cisplatin in patients with advanced nonsmall cell lung carcinoma. *Cancer*. 2003;98:542-553.
9. Ohe Y, Ohashi Y, Kubota K, et al. Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced nonsmall-cell lung cancer: Four-Arm Cooperative Study in Japan. *Ann Oncol* 2007;18:317-323.
10. Scagliotti GV, Kortsik C, Dark GG, et al. Pemetrexed combined with oxaliplatin or carboplatin as first-line treatment in advanced non-small cell lung cancer: a multicenter, randomized, phase II trial. *Clin Cancer Res*. 2005;11:690-696.
11. Cardenal F, Lopez-Cabrerizo MP, Anton A, et al. Randomized phase III study of gemcitabine-cisplatin versus etoposide-cisplatin in the treatment of locally advanced or metastatic non-small cell lung cancer. *J Clin Oncol* 1999;17:12-18.
12. Scagliotti GV, Parikh P, von Pawel J, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage NSCLC. *J Clin Oncol* 2008;26:3543-3551.
13. Schiller JH, Harrington D, Belani CP, et al. Comparison of Four Chemotherapy Regimens for Advanced Non-Small-Cell Lung Cancer. *N Engl J Med* 2002; 346:92-98.
14. Pujol JL, Breton JL, Gervais R, et al. Gemcitabine-docetaxel versus cisplatin-vinorelbine in advanced or metastatic non-small-cell lung cancer: a phase III study addressing the case for cisplatin. *Ann Oncol* 2005;16:602-610.
15. Tan EH, Szczesna A, Krzakowski M, et al. Randomized study of vinorelbine--gemcitabine versus vinorelbine--carboplatin in patients with advanced non-small cell lung cancer. *Lung Cancer*. 2005;49:233-240.
16. Green MR, Manikhas GM, Orlov S, et al. Abraxane , a novel Cremophor -free, albumin-bound particle form of paclitaxel for the treatment of advanced non-small-cell lung cancer. *Ann Oncol*. 2006;17:1263-1268.
17. Rizvi NA, Riely GJ, Azzoli CG, et al. Phase I/II trial of weekly intravenous 130-nm albumin-bound paclitaxel as initial chemotherapy in patients with stage IV non-small-cell lung cancer. *J Clin Oncol*. 2008;26:639-643.
18. Socinski MA, Bondarenko I, Karaseva NA, et al. Weekly nab-paclitaxel in combination with carboplatin versus solvent-based paclitaxel plus carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer: final results of a phase III trial. *J Clin Oncol* 2012;30:2055-2062.
19. Fossella FV, DeVore R, Kerr RN, et al. Randomized phase III trial of docetaxel versus vinorelbine



- or ifosfamide in patients with advanced non-small cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group. *J Clin Oncol* 2000;18:2354-2362.
20. Fidias PM, Dakhil SR, Lyss AP, et al. Phase III study of immediate compared with delayed docetaxel after front-line therapy with gemcitabine plus carboplatin in advanced non-small-cell lung cancer. *J Clin Oncol*. 2009;27:591-598.
  21. Zatloukal P, Kanitz E, Magyar P, Jassem J, et al. Gemcitabine in locally advanced and metastatic non-small cell lung cancer: the Central European phase II study. *Lung Cancer*. 1998;22:243-250.
  22. Sederholm C, Hillerdal G, Lamberg K, et al. Phase III trial of gemcitabine plus carboplatin versus single-agent gemcitabine in the treatment of locally advanced or metastatic non-small-cell lung cancer: the Swedish Lung Cancer Study Group. *J Clin Oncol*. 2005;23:8380-8388.
  23. Pérol M, Chouaid C, Pérol D, et al. Randomized, phase III study of gemcitabine or erlotinib maintenance therapy versus observation, with predefined second-line treatment, after cisplatin-gemcitabine induction chemotherapy in advanced non-small-cell lung cancer. *J Clin Oncol*. 2012;30:3516-24.
  24. Lilenbaum RC, Herndon JE 2nd, List MA, et al. Single-agent versus combination chemotherapy in advanced non-small-cell lung cancer: the cancer and leukemia group B (study 9730). *J Clin Oncol*. 2005;23:190-196.
  25. Ceresoli GL, Gregorc V, Cordio S, et al. Phase II study of weekly paclitaxel as second-line therapy in patients with advanced non-small cell lung cancer. *Lung Cancer*. 2004;44:231-239.
  26. Yasuda K, Igishi T, Kawasaki Y, et al. Phase II study of weekly paclitaxel in patients with non-small cell lung cancer who have failed previous treatments. *Oncology*. 2004;66:347-352.
  27. Hanna N, Shepherd FA, Fossella FV, et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. *J Clin Oncol*. 2004;22:1589-1597.
  28. Langer CJ, et al. Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study. *The Lancet Oncology*. 2016;17:1497-1508.
  29. Leena Gandhi, Delvys Rodríguez-Abreu, et al. Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer. *N Engl J Med* 2018; 378:2078-2092.
  30. Mark A. Socinski, Robert M. Jotte, et al. Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC. *N Engl J Med* 2018; 378:2288-2301.

## Squamous cell carcinoma (PS 0-1)

### No contraindications to the addition of Pembrolizumab or Atezolizumab

藥品名	劑量 mg/m <sup>2</sup>	給藥日	頻率	週期	參考文獻
Pembrolizumab	200 mg	1	Q3W	35	22
Paclitaxel	200	1	Q3W	4	
Carboplatin	AUC 6	1	Q3W	4	

藥品名	劑量 mg/m <sup>2</sup>	給藥日	頻率	週期	參考文獻
Pembrolizumab	200 mg	1	Q3W	35	22
Nab-Paclitaxel	100	1, 8, 15	Q3W		
Carboplatin	AUC 6	1	Q3W		

### Contraindications to the addition of Pembrolizumab or Atezolizumab

藥品名	劑量 mg/m <sup>2</sup>	給藥日	頻率	週期	參考文獻
Carboplatin	AUC 6	1	Q3W		13
Nab-Paclitaxel	100	1, 8, 15	Q3W		

藥品名	劑量 mg/m <sup>2</sup>	給藥日	頻率	週期	參考文獻
Carboplatin	AUC 6	1	Q3W		1
Docetaxel	75	1	Q3W		

藥品名	劑量 mg/m <sup>2</sup>	給藥日	頻率	週期	參考文獻
Carboplatin	AUC 5	1	Q4W		4
Gemcitabine	1000	1, 8, 15	Q4W		

藥品名	劑量 mg/m <sup>2</sup>	給藥日	頻率	週期	參考文獻
Paclitaxel	200	1	Q3W		5
Carboplatin	AUC 6	1	Q3W		

藥品名	劑量 mg/m <sup>2</sup>	給藥日	頻率	週期	參考文獻
Docetaxel	75	1	Q3W		1
Cisplatin	75	1	Q3W		

藥品名	劑量 mg/m <sup>2</sup>	給藥日	頻率	週期	參考文獻
Cisplatin	100	1	Q3W		6
Etoposide	100	1-3	Q3W		

藥品名	劑量 mg/m <sup>2</sup>	給藥日	頻率	週期	參考文獻
Cisplatin	80	1	Q3W		5
Gemcitabine	1000	1, 8	Q3W		

藥品名	劑量 mg/m <sup>2</sup>	給藥日	頻率	週期	參考文獻
Cisplatin	75	1	Q3W		7
Gemcitabine	1250	1, 8	Q3W		

藥品名	劑量 mg/m <sup>2</sup>	給藥日	頻率	週期	參考文獻
Paclitaxel	135	1	Q3W		8
Cisplatin	75	2	Q3W		

藥品名	劑量 mg/m <sup>2</sup>	給藥日	頻率	週期	參考文獻
Gemcitabine	1000	1, 8	Q3W		9
Docetaxel	85	8	Q3W		

藥品名	劑量 mg/m <sup>2</sup>	給藥日	頻率	週期	參考文獻
Gemcitabine	1000	1, 8	Q3W		10
Vinorelbine	25	1, 8	Q3W		

## Squamous cell carcinoma (PS 2)

藥品名	劑量 mg/m <sup>2</sup>	給藥日	頻率	週期	參考文獻
Nab-Paclitaxel	260	1	Q3W		11

藥品名	劑量 mg/m <sup>2</sup>	給藥日	頻率	週期	參考文獻
Carboplatin	AUC 6	1	Q3W		12, 13
Nab-Paclitaxel	100	1, 8, 15	Q3W		

藥品名	劑量 mg/m <sup>2</sup>	給藥日	頻率	週期	參考文獻
Carboplatin	AUC 6	1	Q3W		1
Docetaxel	75	1	Q3W		

藥品名	劑量 mg/m <sup>2</sup>	給藥日	頻率	週期	參考文獻
Carboplatin	325	1			2
Etoposide	100	1-3			

藥品名	劑量 mg/m <sup>2</sup>	給藥日	頻率	週期	參考文獻
Carboplatin	AUC 4-5	1	Q4W		3
Etoposide	50mg PO BID	1-14 or 1-21	Q4W		

藥品名	劑量 mg/m <sup>2</sup>	給藥日	頻率	週期	參考文獻
Carboplatin	AUC 5	1	Q4W		4
Gemcitabine	1000	1, 8, 15	Q4W		

藥品名	劑量 mg/m <sup>2</sup>	給藥日	頻率	週期	參考文獻
Carboplatin	AUC 6	1	Q3W		5
Paclitaxel	200	1	Q3W		

藥品名	劑量 mg/m <sup>2</sup>	給藥日	頻率	週期	參考文獻
Docetaxel	75	1	Q3W		14, 15

藥品名	劑量 mg/m <sup>2</sup>	給藥日	頻率	週期	參考文獻
Gemcitabine	1250	1, 8, 15	Q4W		16

藥品名	劑量 mg/m <sup>2</sup>	給藥日	頻率	週期	參考文獻
Gemcitabine	1250	1, 8	Q3W		17, 18

藥品名	劑量 mg/m <sup>2</sup>	給藥日	頻率	週期	參考文獻
Gemcitabine	1000	1, 8	Q3W		9
Docetaxel	85	8	Q3W		

藥品名	劑量 mg/m <sup>2</sup>	給藥日	頻率	週期	參考文獻
Gemcitabine	1000	1, 8	Q3W		10
Vinorelbine	25	1, 8	Q3W		

藥品名	劑量 mg/m <sup>2</sup>	給藥日	頻率	週期	參考文獻
Paclitaxel	225	1	Q3W		19

藥品名	劑量 mg/m <sup>2</sup>	給藥日	頻率	週期	參考文獻
Paclitaxel	80	1, 8, 15	Q4W		20, 21

## 參考文獻

1. Fossella F, Periera JR, von Pawel J, et al. Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group. *J Clin Oncol* 2003;21(16):3016-3024.
2. Klastersky J, Sculier JP, Lacroix H, et al. A randomized study comparing cisplatin or carboplatin with etoposide in patients with advanced non-small-cell lung cancer: European Organization for Research and Treatment of Cancer Protocol 07861. *J Clin Oncol* 1990;8:1556-1562.
3. Frasci G, Comella P, Panza N, et al. Carboplatin-oral etoposide personalized dosing in elderly non-small cell lung cancer patients. Gruppo Oncologico Cooperativo Sud-Italia. *Eur J Cancer*. 1998;34:1710-1714.
4. Danson S, Middleton MR, O'Byrne KJ, et al. Phase III trial of gemcitabine and carboplatin versus mitomycin, ifosfamide, and cisplatin or mitomycin, vinblastine, and cisplatin in patients with advanced nonsmall cell lung carcinoma. *Cancer*. 2003;98:542-553.
5. Ohe Y, Ohashi Y, Kubota K, et al. Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small cell lung cancer: Four-Arm Cooperative Study in Japan. *Ann Oncol* 2007;18:317-323.
6. Cardenal F, Lopez-Cabrerizo MP, Anton A, et al. Randomized phase III study of gemcitabine-cisplatin versus etoposide-cisplatin in the treatment of locally advanced or

- metastatic non-small cell lung cancer. *J Clin Oncol* 1999;17:12-18.
7. Scagliotti GV, Parikh P, von Pawel J, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage NSCLC. *J Clin Oncol* 2008;26:3543-3551.
  8. Schiller JH, Harrington D, Belani CP, et al. Comparison of Four Chemotherapy Regimens for Advanced Non-Small-Cell Lung Cancer. *N Engl J Med* 2002; 346:92-98.
  9. Pujol JL, Breton JL, Gervais R, et al. Gemcitabine-docetaxel versus cisplatin-vinorelbine in advanced or metastatic non-small-cell lung cancer: a phase III study addressing the case for cisplatin. *Ann Oncol* 2005;16:602-610.
  10. Tan EH, Szczesna A, Krzakowski M, et al. Randomized study of vinorelbine--gemcitabine versus vinorelbine--carboplatin in patients with advanced non-small cell lung cancer. *Lung Cancer*. 2005;49:233-240.
  11. Green MR, Manikhas GM, Orlov S, et al. Abraxane , a novel Cremophor -free, albumin-bound particle form of paclitaxel for the treatment of advanced non-small-cell lung cancer. *Ann Oncol*. 2006;17:1263-1268.
  12. Rizvi NA, Riely GJ, Azzoli CG, et al. Phase I/II trial of weekly intravenous 130-nm albumin-bound paclitaxel as initial chemotherapy in patients with stage IV non-small-cell lung cancer. *J Clin Oncol*. 2008;26:639-643.
  13. Socinski MA<sup>1</sup>, Bondarenko I, Karaseva NA, et al. Weekly nab-paclitaxel in combination with carboplatin versus solvent-based paclitaxel plus carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer: final results of a phase III trial. *J Clin Oncol* 2012;30:2055-2062.
  14. Fossella FV, DeVore R, Kerr RN, et al. Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group. *J Clin Oncol* 2000;18:2354-2362.
  15. Fidias PM, Dakhil SR, Lyss AP, et al. Phase III study of immediate compared with delayed docetaxel after front-line therapy with gemcitabine plus carboplatin in advanced non-small-cell lung cancer. *J Clin Oncol*. 2009;27:591-598.
  16. Zatloukal P, Kanitz E, Magyar P, Jassem J, et al. Gemcitabine in locally advanced and metastatic non-small cell lung cancer: the Central European phase II study. *Lung Cancer*. 1998;22:243-250.
  17. Sederholm C, Hillerdal G, Lamberg K, et al. Phase III trial of gemcitabine plus carboplatin versus single-agent gemcitabine in the treatment of locally advanced or metastatic non-small-cell lung cancer: the Swedish Lung Cancer Study Group. *J Clin Oncol*. 2005;23:8380-8388.
  18. Pérol M, Chouaid C, Pérol D, et al. Randomized, phase III study of gemcitabine or erlotinib maintenance therapy versus observation, with predefined second-line treatment, after cisplatin-gemcitabine induction chemotherapy in advanced non-small-cell lung cancer. *J Clin Oncol*. 2012;30:3516-24.

19. Lilenbaum RC, Herndon JE 2nd, List MA, et al. Single-agent versus combination chemotherapy in advanced non-small-cell lung cancer: the cancer and leukemia group B (study 9730). *J Clin Oncol*. 2005;23:190-196.
20. Ceresoli GL, Gregorc V, Cordio S, et al. Phase II study of weekly paclitaxel as second-line therapy in patients with advanced non-small cell lung cancer. *Lung Cancer*. 2004;44:231-239.
21. Yasuda K, Igishi T, Kawasaki Y, et al. Phase II study of weekly paclitaxel in patients with non-small cell lung cancer who have failed previous treatments. *Oncology*. 2004;66:347-352.
22. Luis Paz-Ares, Alexander Luft, et al. Pembrolizumab plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer. *N Engl J Med* 2018; 379:2040-2051.